Practice management in the era of anti-VEGF therapy (Part I)

Article

Identifying the bottlenecks that are preventing effective management of neovascular AMD.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
EYLEA 8mg in focus: Key learnings from the pivotal trials
EYLEA 8mg in focus: Key learnings from the pivotal trials
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
How embracing opposition sends clinicians home from COPHy with more useful takeaways
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Angiogenesis 2025: The global forecast for AI-driven home OCT
EYLEA’s unique MoA: What is the rationale for the higher molar dose?
EYLEA’s unique MoA: What is the rationale for the higher molar dose?
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Charles Wykoff, MD, PhD, presents on diabetic retinopathy and "the dream of reperfusion" at Floretina ICOOR 2024
Related Content
The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 5th 2025
Article

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person types on a computer. An AI brain is over the screen. Concept image for artificial intelligence, therapy planning assistant system, TPS, Europe, CE mark. Image credit: ©New Africa – stock.adobe.com

EU issues CE mark for AI therapy planning assistant from deepeye Medical

Jordana Joy
June 2nd 2025
Article

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An image of two containers of vitamin B supplements. Concept image for choline, b6, b9 and b12 vitamins in neuroprotection for glaucoma. ©itsflowingtothesoul – stock.adobe.com

Research indicates B vitamins and choline provide neuroprotection against glaucoma

Lynda Charters
May 26th 2025
Article

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

A single-shot, 130-degree OCTA image of the retina captured using DREAM OCT. Image courtesy of Intalight

EMA issues CE mark for DREAM OCT (Intalight)

Jordana Joy
May 22nd 2025
Article

The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities

© 2025 MJH Life Sciences

All rights reserved.